These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
4. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545 [TBL] [Abstract][Full Text] [Related]
5. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study. Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955 [TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma. Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472 [TBL] [Abstract][Full Text] [Related]
7. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718 [TBL] [Abstract][Full Text] [Related]
8. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets. Chin-Yee IH; Keeney M; Stewart AK; Belch A; Bence-Buckler I; Couban S; Howson-Jan K; Rubinger M; Stewart D; Sutherland R; Paragamian V; Bhatia M; Foley R Bone Marrow Transplant; 2002 Dec; 30(12):851-60. PubMed ID: 12476276 [TBL] [Abstract][Full Text] [Related]
9. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
10. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF. Callera F; Cavenaghi L; de Melo CM Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728 [TBL] [Abstract][Full Text] [Related]
11. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Boiron JM; Marit G; Fabéres C; Cony-Makhoul P; Foures C; Ferrer AM; Cristol G; Sarrat A; Girault D; Reiffers J Bone Marrow Transplant; 1993 Jul; 12(1):49-55. PubMed ID: 8104070 [TBL] [Abstract][Full Text] [Related]
12. Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens. Vogel W; Kopp HG; Kanz L; Einsele H J Cancer Res Clin Oncol; 2002 Jul; 128(7):380-4. PubMed ID: 12136252 [TBL] [Abstract][Full Text] [Related]
13. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278 [TBL] [Abstract][Full Text] [Related]
14. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354 [TBL] [Abstract][Full Text] [Related]
15. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma. Bilgrami S; Bona RD; Edwards RL; Li Z; Naqvi B; Shaikh A; Furlong F; Fox J; Clive J; Tutschka PJ Bone Marrow Transplant; 2001 Jul; 28(2):137-43. PubMed ID: 11509931 [TBL] [Abstract][Full Text] [Related]
16. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046 [TBL] [Abstract][Full Text] [Related]
17. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma. Annunziata M; Celentano M; Pocali B; D'Amico MR; Palmieri S; Viola A; Copia C; Falco C; Del Vecchio L; Ferrara F Ann Hematol; 2006 Jun; 85(6):394-9. PubMed ID: 16538502 [TBL] [Abstract][Full Text] [Related]
18. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433 [TBL] [Abstract][Full Text] [Related]
19. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen. Dawson MA; Schwarer AP; Muirhead JL; Bailey MJ; Bollard GM; Spencer A Bone Marrow Transplant; 2005 Sep; 36(5):389-96. PubMed ID: 15980882 [TBL] [Abstract][Full Text] [Related]
20. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]